Abstract: The present disclosure provides a preparation method of dihydroquercetin, belonging to the field of synthesis of drugs. The method includes steps of: adjusting reaction solvent water to be alkaline with an alkalizing reagent, to obtain an alkaline aqueous solution; dissolving quercetin dihydrate in the alkaline aqueous solution, and adding a sulfite binary combined reducing agent to carry out reduction reaction, to obtain an endpoint reduction reaction solution; diluting the endpoint reduction reaction solution with water, and then acidizing, aging, and filtering the resultant to obtain a filtrate and a filter cake; subjecting the filtrate to extraction, washing, drying, and vacuum concentration to obtain a concentrated crude product; and repeatedly crystallizing the concentrated crude product to obtain dihydroquercetin. The preparation method of the present disclosure has readily available raw materials, a simple process, and low production costs, and is particularly suitable for industrial production.

Abstract: The object of the present invention is to provide a method for producing glycolide, with which a production rate of glycolide can be further enhanced. The method for producing glycolide that achieves the object described above includes: an oligomer preparation step of heating an aqueous glycolic acid solution and subjecting glycolic acid contained in the aqueous glycolic acid solution to dehydrating polycondensation, to obtain a glycolic acid oligomer; and a depolymerization step of depolymerizing the glycolic acid oligomer in the presence of ferrous ions to obtain glycolide.

Abstract: The present invention relates to silole and germole fused ring photochromic compounds represented, with some embodiments, by the following Formula (Ia), (Ia) With reference to Formula (Ia): M includes Si or Ge; Ring A and Ring B each independently include aryl or heteroaryl; and the photochromic compound is a thermally reversible photochromic compound. The present invention also relates to photochromic compositions and photochromic articles, such as photochromic ophthalmic articles that include one or more photochromic compounds represented, with some embodiments, by Formula (Ia).

Abstract: Tricyclic mitogen-activated protein kinases kinase 4 (MKK4) inhibitor compounds useful for promoting liver regeneration or reducing hepatocyte death by selectively inhibiting MKK4 over protein kinases JNK and MKK7.

Abstract: A composition includes a functionalized fluorescent dye. The functionalized fluorescent dye includes an isothiocyanate-containing dye that is functionalized with a functional group. The functional group includes a primary amine. The functionalized fluorescent dye can be mixed with a fluid to form a tracer fluid for tracing fluid flow in a subterranean formation.

Abstract: The present disclosure relates to compounds and compositions that inhibit the NLRP3 inflammasome, for example, or a pharmaceutically acceptable salt thereof. Also disclosed are methods for treating, and in particular methods for treating macular degeneration, e.g., dry age-related macular degeneration (AMD) and wet AMD, Alzheimer's disease, multiple sclerosis, and Parkinson's disease, using compounds and compositions that inhibit the NLRP3 inflammasome.

Abstract: The present invention relates to novel crystalline polymorphs of 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-4-piperidinamine monobenzenesulfonate, and to methods for their preparation. The invention further relates to pharmaceutical compositions containing one or more forms and optionally one or more suitable pharmaceutical carriers. The invention also relates to methods of using the crystalline polymorphs of the invention in the treatment of disease.

Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

Abstract: The present disclosure provides compounds and nanostructures having one or more quaternary ammonium salts, compositions including the compounds and nanostructures, and methods useful for treating conditions using the compounds, nanostructures, and compositions. In at least one aspect, a compound is represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein: Q is fluoro, chloro, bromo, or iodo; each of s, b, and n is independently an integer from about 10 to about 100; and each of v, j, p, z, q, x and m is independently an integer from 1 to about 20.

Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).

Abstract: Dioxetane compounds represented by Formula I below, and methods of using the dioxetane compounds in the detection of presence or absence, quantification, and identification of microorganisms including bacteria, bacterial fragments (e.g., LPS, endotoxin), viruses, and fungi by means of chemiluminescence.

Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to 4-(2-hydroxyethyl)-morpholine is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Abstract: This disclosure features chemical entities of formula I (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: The present disclosure provides a method for preparing diselenide compound. A polar solvent is added to a dihydroflavonol compound, heated to 80° C.˜100° C., kept for 40˜50 minutes, then the base in the amount of 0.4˜1.0 times the amount of the dihydroflavonol compound is added and reacted at 80° C.˜100° C. for 5˜60 minutes, then selenium dioxide in the amount of 0.6˜1.2 times the amount of dihydroflavonol compounds at 80° C.˜100° C. The diselenide compound of the dihydroflavonol compound is obtained by reacting at a temperature of 80° C.˜100° C. for 30˜150 minutes. The method of the present disclosure has mild reaction, low pollution, does not require an anhydrous and oxygen-free environment, and is suitable for large-scale industrial production.

Abstract: According to the present invention a process is provided for producing glycolide which comprises contacting glycolaldehyde dimer with an oxidizing agent to produce a glycolide product. Preferably, the process is carried out in an aprotic environment, such as in a reaction mixture comprising the glycolaldehyde dimer, the oxidizing agent, the glycolide product and an aprotic solvent.

Abstract: The present disclosure provides compounds of Formula (II) wherein R1, R2, R3, R4, R5, W1, W2, W3, X, Y, and A are as described herein. The disclosed compounds modulate CD73 activity. The present disclosure also provides, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity.

Abstract: The present invention provides a thiophene carboxamide compound of the following General Formula (I), which is a novel fluorine-substituted biphenyl carboxamide-based compound, and provides a useful compound, as an agricultural and horticultural plant disease control agent, exhibiting an excellent control effect at a low dose. wherein, R, R1, R2, R3, Xm, and Y are each as defined in the specification.

Abstract: Disclosed are a crystal form (I) as an inhibitor of ACC1 and ACC2, a preparation method therefor, and the use thereof in the preparation of a drug as an inhibitor of ACC1 and ACC2.

Abstract: The present disclosure relates to crystalline solid forms of a stimulator of soluble guanylate cyclase (sGC), Compound I: Also provided herein are methods for the preparation of these solid forms. The invention also relates to pharmaceutical formulations and dosage forms comprising these solid forms and their uses thereof, alone or in combination with one or more additional agents, for treating and/or preventing various diseases or disorders; these diseases or disorders are ones that may benefit from sGC stimulation or from an increase in the concentration of nitric oxide (NO) and/or cyclic guanosine monophosphate (cGMP).

Abstract: A novel non-fluorescent rhodamine dye forms a twisted intramolecular charge transfer state. A substituent that causes steric hindrance is introduced at an ortho position of a dimethylamino group on the xanthene ring of tetramethylrhodamine, which is a general rhodamine that exhibits strong fluorescence, and a certain amount of twist is imparted in a ground state. As a result, the formation of the twisted intramolecular charge transfer state is promoted in the excited state and non-fluorescence is exhibited.